Sankalp “Sam” Gokhale, M.D., is a U.S. board-certified neurologist who has experience in building clinical development and medical functions, extensive interactions with global regulatory authorities in the rare auto-immune neurology space, and robust networks of global key opinion leaders. Prior to Arialys, Sam served as Senior Vice President, Head of Clinical Development at Dianthus Therapeutics, where he was instrumental in its transition from a private to public company. At Dianthus, he built the clinical development function which drove three successful INDs in autoimmune rare disease neurology indications in one year. Prior to Dianthus, Sam held roles in clinical development with progressively increasing responsibilities at Radius Health, leading the clinical development of oral CBD for multiple rare neuropsychiatric and epilepsy indications; and at Alexion Pharmaceuticals, leading multiple Phase 2 and 3 global clinical trials (pediatric and adult) for eculizumab and ravulizumab in myasthenia gravis, with U.S. FDA approval of ravulizumab in myasthenia gravis. Dr. Gokhale completed his neurology residency at Beth Israel Deaconess Medical Center / Boston Children's Hospital at Harvard Medical School and a fellowship in neurological critical care at Duke University Medical Center and received his M.B.A. from the University of Arizona. Prior to transitioning to the biopharmaceutical industry, Sam was instrumental in building the successful neurocritical care program at the Banner - University Medical Center in Tucson, Arizona.